AlloVir, Inc. (ALVR)

NASDAQ: ALVR · IEX Real-Time Price · USD
9.15 -1.25 (-12.02%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap596.04M
Revenue (ttm)n/a
Net Income (ttm)-139.22M
Shares Out65.14M
EPS (ttm)-2.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume309,475
Open10.21
Previous Close10.40
Day's Range9.13 - 10.37
52-Week Range9.13 - 47.00
Betan/a
AnalystsBuy
Price Target42.75 (+367.2%)
Earnings DateNov 9, 2021

About ALVR

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and hu...

IndustryBiotechnology
IPO DateJul 30, 2020
Employees110
Stock ExchangeNASDAQ
Ticker SymbolALVR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 42.75, which is an increase of 367.21% from the latest price.

Price Target
$42.75
(367.21% upside)
Analyst Consensus: Buy

News

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Ade...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus...

1 week ago - Business Wire

AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present a...

2 weeks ago - Business Wire

AlloVir Announces Departure of Chief Medical Officer Augustin Melian

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially lea...

1 month ago - Business Wire

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 6...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 ...

1 month ago - Business Wire

AlloVir to Host Virtual Investor Event

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST....

1 month ago - Business Wire

AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Vir...

2 months ago - Business Wire

AlloVir Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the third quarter ended September 30, 2021. The company also s...

2 months ago - Business Wire

FDA Grants Orphan Drug Designation (ODD) to AlloVir's Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Desi...

3 months ago - Business Wire

Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir's Investigational SARS-CoV-2-Specific T Cell Therapy...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical and early clinical data demonstrating that ALVR109, an investigat...

3 months ago - Business Wire

AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conferenc...

4 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - August 26, 2021) - Levi & Korsinsky announces it has commenced an investigation of Avalara, Inc. (NASDAQ: ALVR) concerning possible breaches of fiduciary duty. To o...

4 months ago - Newsfile Corp

AlloVir Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2021....

5 months ago - Business Wire

AlloVir Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the first quarter ended March 31, 2021....

8 months ago - Business Wire

AlloVir Appoints Diana M. Brainard, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company's...

9 months ago - Business Wire

AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Globa...

11 months ago - Business Wire

AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-conc...

11 months ago - Business Wire

AlloVir Reports Full Year 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial resu...

11 months ago - Business Wire

AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster prese...

1 year ago - Business Wire

AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healt...

1 year ago - Business Wire

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Mu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investi...

1 year ago - Business Wire

Company Profile for AlloVir

--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened imm...

1 year ago - Business Wire

Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at th...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demon...

1 year ago - Business Wire

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specif...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62n...

1 year ago - Business Wire

AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Confere...

1 year ago - Business Wire

AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support ...

1 year ago - GlobeNewsWire